Ultragenyx Pharmaceutical (RARE) EBIAT (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EBIAT of -$185.0 million for Q1 2026, down 22.52% year-over-year from -$238.8 million in Q1 2025, and down 43.91% on a QoQ basis from -$128.6 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of EBIAT data on file, last reported at -$185.0 million in Q1 2026.
- Quarterly EBIAT fell 22.52% year-over-year to -$185.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$608.9 million (down 10.85% YoY) and the FY2025 annual result came in at -$575.0 million, down 1.05% from the prior year.
- EBIAT eased to -$185.0 million in Q1 2026 per RARE's latest filing, from -$128.6 million in the prior quarter.
- Across five years, EBIAT topped out at -$115.0 million in Q2 2025 and bottomed at -$245.1 million in Q3 2022.
- The 5-year median for EBIAT is -$152.3 million (2022), against an average of -$155.5 million.
- The widest annual swing landed in 2022, when EBIAT plunged 235.77%; it then surged 34.87% in 2023.
- Tracing RARE's EBIAT over 5 years: stood at -$151.8 million in 2022, then advanced by 18.63% to -$123.6 million in 2023, then fell by 7.81% to -$133.2 million in 2024, then increased by 3.49% to -$128.6 million in 2025, then sank by 43.91% to -$185.0 million in 2026.
- Per Business Quant, the three latest RARE EBIAT figures stand at -$185.0 million (Q1 2026), -$128.6 million (Q4 2025), and -$180.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -185.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.00 Mn |
| Dec 31, 2025 | -128.56 Mn |
| Sep 30, 2025 | -180.41 Mn |
| Jun 30, 2025 | -114.95 Mn |
| Mar 31, 2025 | -151.00 Mn |
| Dec 31, 2024 | -133.20 Mn |
| Sep 30, 2024 | -133.52 Mn |
| Jun 30, 2024 | -131.60 Mn |
| Mar 31, 2024 | -170.68 Mn |
| Dec 31, 2023 | -123.55 Mn |
| Sep 30, 2023 | -159.65 Mn |
| Jun 30, 2023 | -159.83 Mn |
| Mar 31, 2023 | -163.97 Mn |
| Dec 31, 2022 | -151.83 Mn |
| Sep 30, 2022 | -245.11 Mn |
| Jun 30, 2022 | -158.16 Mn |
| Mar 31, 2022 | -152.32 Mn |
| Dec 31, 2021 | -122.46 Mn |
| Sep 30, 2021 | -73.00 Mn |
| Jun 30, 2021 | -122.43 Mn |
| Mar 31, 2021 | -136.14 Mn |
| Dec 31, 2020 | -24.01 Mn |
| Sep 30, 2020 | -68.85 Mn |
| Jun 30, 2020 | 25.32 Mn |
| Mar 31, 2020 | -119.03 Mn |
| Dec 31, 2019 | -93.81 Mn |
| Sep 30, 2019 | -112.99 Mn |
| Jun 30, 2019 | -99.17 Mn |
| Mar 31, 2019 | -96.76 Mn |
| Dec 31, 2018 | -87.83 Mn |
| Sep 30, 2018 | -87.31 Mn |
| Jun 30, 2018 | -52.73 Mn |
| Mar 31, 2018 | 30.25 Mn |
| Dec 31, 2017 | 7.50 Mn |
| Sep 30, 2017 | -79.23 Mn |
| Jun 30, 2017 | -72.89 Mn |
| Mar 31, 2017 | -68.29 Mn |
| Dec 31, 2016 | -71.29 Mn |
| Sep 30, 2016 | -64.91 Mn |
| Jun 30, 2016 | -56.92 Mn |
| Mar 31, 2016 | -52.76 Mn |
| Dec 31, 2015 | -55.22 Mn |
| Sep 30, 2015 | -39.23 Mn |
| Jun 30, 2015 | -29.79 Mn |
| Mar 31, 2015 | -21.38 Mn |
| Dec 31, 2014 | -16.74 Mn |
| Sep 30, 2014 | -15.85 Mn |
| Jun 30, 2014 | -13.59 Mn |
| Mar 31, 2014 | -13.63 Mn |
| Dec 31, 2013 | -11.32 Mn |
| Sep 30, 2013 | -8.43 Mn |
| Jun 30, 2013 | -8.59 Mn |
| Mar 31, 2013 | -6.74 Mn |